Cadila was founded in 1952 by Ramanbhai Patel, formerly a lecturer in the L.M. College of Pharmacy, and his business partnerIndravadan Modi. It evolved over the next four decades into an established pharmaceutical company. In 1995 the Patel and Modi families split; the Modi family's share was moved into a new company called Cadila Pharmaceuticals Ltd., and Cadila Healthcare Ltd became the Patel family's holding company. Cadila Healthcare had its initial public offering on the Bombay Stock Exchange in 2000 as stock code 532321. In 2015 the company acquired another Indian pharmaceutical company called German Remedies. On 25 June 2007, the company acquired Química e Farmacêutica Nikkho do Brasil Ltda as part of Zydus Healthcare Brasil Ltda. In 2010, Cadila Healthcare received a Wellcome Trust Award under the "R&D for Affordable Healthcare in India" initiative. In 2014, Cadila Healthcare launched the world's first adalimumab biosimilar under the brand nameExemptia at one-fifth the originator's price. Zydus Cadila Healthcare has also launched its first research based drug molecule Saroglitazar in treatment of Diabetic Dyslipidemia under brand name "Lipaglyn". SoviHep is the first sofosbuvir brand launched in India by Zydus in year 2015. In 2019, injectable ketorolac tromethamine manufactured by Zydus was recalled due to microbial growth.
Products
From nine pharmaceutical production operations in India as well as a Zydus Cadila develops and manufactures a large range of pharmaceuticals as well as diagnostics, herbal products, skin care products and other OTC products. Starting from late 2015, having concluded a voluntary license agreement with Gilead, the company also produces the generics for hepatitis C treatment. The company makes active pharmaceutical ingredients at three sites in India, Ankleshwar plants, Vadodara plant, and Patalganga plant.
Corporate control
Zydus Cadila's major shareholder remains the Patel family. Pankaj Patel, son of the founder, is Chairman of the company. In 2004 Pankaj Patel was included by Forbes magazine in its annual List of India's richest people. As of 2020 Forbes estimates Patel's net worth at US $3.9 billion, making him India's 46th richest person.
